Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo

Journal of Virology

Volumn 72, Issue 4, 1998, Pages 3300-3306

  Zennou, Véronique ^a   Mammano, Fabrizio ^a   Paulous, Sylvie ^a   Mathez, Dominique ^b   Clavel, François ^a  

^a INSTITUT PASTEUR   (France)

^b RAYMOND POINCARÉ HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; POL PROTEIN; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CASE REPORT; HELA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PROCESSING; RNA SEQUENCE; VIRUS PARTICLE; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS TITRATION;

EID: 0031946007     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.72.4.3300-3306.1998     Document Type: Article

References (32)

1. Barrie, K. A., E. E. Perez, S. L. Lamers, W. G. Farmerie, B. M. Dunn, J. W. Sleasman, and M. M. Goodenow. 1996. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within Gag/Pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1. Virology 219: 407-416.
2. Borman, A., S. Paulous, and F. Clavel. 1996. Resistance of HIV-1 to protease inhibitors: selection of resistance mutations in the presence and in the absence of the drug. J. Gen. Virol. 77:419-426.
3. Charneau, P., G. Mirambeau, P. Roux, S. Paulous, H. Buc, and F. Clavel. 1994. HIV-1 reverse transcription: a termination step at the center of the genome. J. Mol. Biol. 241:651-662.
4. Condra, J. H., D. J. Holder, W. A. Schleif, O. M. Blahy, R. M. Danovich, L. J. Gabryelski, D. J. Graham, D. Laird, J. C. Quintero, A. Rhodes, H. L. Robbins, E. Roth, M. Shivaprakash, T. Yang, J. A. Chodakewitz, P. J. Deutsch, R. Y. Leavitt, F. E. Massari, J. W. Mellors, K. E. Squires, R. T. Steigbigel, H. Teppler, and E. A. Emini. 1996. Genetic correlates of in vivo viral resistance to Indinavir, a human immunodeficiency virus type 1 protease inhibitor. J. Virol. 70:8270-8276.
5. Condra, J. H., W. A. Schleif, O. M. Blahy, L. J. Gabryelski, D. J. Graham, J. C. Qnintero, A. Rhodes, H. L. Hobbins, E. Roth, M. Shivaprakash, D. L. Titus, T. Yang, H. Teppler, K. E. Squires, P. J. Deutsch, and E. A. Emini. 1995. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374:569-571.
6. Croteau, G., L. Doyon, D. Thibeault, G. McKercher, L. Pilote, and D. Lamarre. 1997. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J. Virol. 71:1089-1096.
7. Debouck, C. 1992. The HIV-1 protease as a therapeutic target for AIDS. AIDS Res. Hum. Retroviruses 8:153-164.
8. Deeks, S. G., M. Smith, M. Holodniy, and J. O. Kahn. 1997. HIV-1 protease inhibitors: a review for clinicians. JAMA 277:145-153.
9. Doyon, L., F. Poulin, L. Pilote, C. Clouette, D. Thibeault, G. Croteau, and D. Lamarre. 1996. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J. Virol. 70:3763-3769.
10. Erickson, J. W. 1995. The not-so-great escape. Nat. Struct. Biol. 2:523-529.
11. Eustice, D., P. Feldman, A. Colberg-Poley, R. Buckery, and R. Neubauer. 1991. A sensitive method for the detection of β-galactosidase in transfected mammalian cells. BioTechniques 11:739-743.
12. Gulick, R. M., J. W. Mellors, D. Havlir, J. J. Eron, C. Gonzalez, D. McMahon, D. D. Richman, F. T. Valentine, L. Jonas, A. Meibohm, E. A. Emini, and J. A. Chodakewitz. 1997. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 337:734-739.
13. Gulnick, S. V., L. I. Suvorov, B. Liu, B. Yu, B. Anderson, H. Mitsuya, and J. W. Erickson. 1995. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry 34: 9282-9287.
14. Ho, D., T. Toyoshima, H. Mo, D. Kempf, D. Norbeck, C. Chen, N. Wideburg, S. Burt, J. Erickson, and M. Singh. 1994. Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor. J. Virol. 68:2016-2020.
15. Kaplan, A., S. Michael, R. Wehbie, M. Knigge, D. Paul, L. Everitt, D. Kempf, D. Norbeck, J. Erickson, and R. Swanstrom. 1994. Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease. Proc. Natl. Acad. Sci. USA 91:5597-5601.
16. Kempf, D., R. Rode, Y. Xu, E. Sun, A. Japour, S. Danner, C. Boucher, J. Leonard, and A. Molla. 1997. The durability of response to protease inhibitor therapy is predicted by viral load, abstr. 62. In International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication.
17. Kozal, M., N. Shah, N. Shen, R. Yang, R. Fucini, T. Merigan, D. Richman, D. Morris, E. Hubbell, M. Chee, and T. Gingeras. 1996. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat. Med. 2:753-759.
18. Lech, W., G. Wang, Y. Yang, Y. Chee, K. Dorman, D. McCrae, L. Lazzeroni, J. Erickson, J. Sinsheimer, and A. Kaplan. 1996. In vivo sequence diversity of the protease of human immunodeficiency virus type 1: presence of protease inhibitor-resistant variants in untreated subjects. J. Virol. 70:2038-2043.
19. Lin, Y., X. Lin, L. Hong, S. Foundling, R. L. Heinrickson, S. Thaisrivongs, W. Leelamanit, D. Raterman, M. Shah, B. M. Dunn, and J. Tang. 1995. Effect of point mutations on the kinetics and the inhibition of human immunodeficiency virus type 1 protease: relationship to drug resistance. Biochemistry 34:1143-1152.
20. Markowitz, M., Y. Cao, A. Hurley, et al. 1996. Triple therapy with AZT, 3TC and ritonavir in 12 subjects newly infected with HIV-1, abstr. Th. B. 933. In Abstracts of the XI International Conference on AIDS.
21. Markowitz, M., H. Mo, D. Kempf, D. Norbeck, T. Bhat, J. Erickson, and D. Ho. 1995. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J. Virol. 69:701-706.
22. Mathez, D., P. de Truchis, I. Gorin, C. Katlama, G. Pialoux, A. G. Saimot, R. Tubiana, J. P. Chauvin, P. Bagnarelli, M. Clementi, and J. Leibowitch. 1996. Ritonavir, AZT, ddC, as a triple combination in AIDS patients, abstr. 285. In Third Conference on Retroviruses and Opportunistic Infections.
23. Molla, A., D. Kempf, M. Korneyeva, Q. Gao, P. Shipper, H. Mo, M. Markowitz, S. Vasavanonda, T. Chernyavskyi, P. Niu, N. Lyons, A. Hsu, G. Granneman, D. Ho, C. Boucher, J. Leonard, and D. Norbeck. 1996. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat. Med. 2:760-766.
24. Myers, G., S. Wain-Hobson, L. Henderson, B. Korber, K. Jeang, and G. Pavlakis. 1994. Human retroviruses and AIDS. Los Alamos National Laboratory, Los Alamos, N.Mex.
25. Nijhuis, M., R. Schuurman, P. Schipper, D. de Jong, T. van Bommel, T. de Groot, A. Molla, J. Borleffs, S. Danner, and C. Boucher. 1997. Reduced replication potential of HIV-1 variants initially selected under Ritonavir therapy is restored upon selection of additional substitutions. In Abstracts of the International Discussion Meeting on HIV Population Dynamics, Variation and Drug Resistance.
26. Partaledis, J., K. Yamagushi, M. Tisdale, E. Blair, C. Falcione, B. Maschera, R. Myers, S. Pazhanisamy, O. Futer, A. Cullinan, C. Stuver, R. Byrn, and D. Livingston. 1995. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J. Virol. 69: 5228-5235.
27. Patick, A., R. Rose, J. Greytok, C. Bechtold, M. Hermsmeier, P. Chen, J. Barrish, R. Zahler, R. Colonno, and P. Lin. 1995. Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor. J. Virol. 69:2148-2152.
28. Pettit, S., M. Moody, R. Wehbie, A. Kaplan, P. Nantermet, C. Klein, and R. Swanstrom. 1994. The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. J. Virol. 68:8017-8027.
29. Roberts, N. A. 1995. Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors. AIDS 9:S27-S32.
30. Rose, R., Y. Gong, J. Greytok, C. Bechtold, B. Terry, B. Robinson, M. Alam, R. Colonno, and P. Lin. 1996. Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors. Proc. Natl. Acad. Sci. USA 93:1648-1653.
31. Sardana, V. V., A. J. Schlabach, P. Graham, B. L. Bush, J. H. Condra, J. C. Culberson, L. Gotlib, D. J. Graham, N. E. Kohl, R. L. LaFemina, C. L. Schneider, B. S. Wolanski, J. A. Wolfgang, and E. A. Emini. 1994. Human immunodeficiency virus type 1 protease inhibitors: evaluation of resistance engendered by amino-acid substitutions in the enzyme substrate binding site. Biochemistry 33:2004-2010.
32. Winslow, D. L., S. Stack, R. King, H. Scarnati, A. Bincsik, and M. J. Otto. 1995. Limited sequence diversity in the HIV type 1 protease gene from clinical isolates and in vivo susceptibility to HIV protease inhibitors. AIDS Res. Hum. Retroviruses 11:107-113.